Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q47901999

about

Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4 Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis.Immune selection in neoplasia: towards a microevolutionary model of cancer development.Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial.Serum efficacy biomarkers for oncology.Targeting apoptosis in autoimmune hepatitis.Tumor cell secretion of soluble factor(s) for specific immunosuppression.Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype.Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease.Serum levels of soluble fas in patients with multinodular goiter.Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response.Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection.Date fruits inhibit hepatocyte apoptosis and modulate the expression of hepatocyte growth factor, cytochrome P450 2E1 and heme oxygenase-1 in carbon tetrachloride-induced liver fibrosis.Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population.

P2860

Q27486569-14E08237-EDC1-45D0-B419-6AF209A367F1 Q33640766-D7BF580B-541E-451B-AC4B-6F73FA18A202 Q33787621-D31916A5-C6F7-4EFF-9B49-5D77194EB683 Q33801352-1DDFC97E-28B9-44A4-8FA3-5E92C6F6C2EE Q33948688-654318CA-25D1-46E8-9FFA-408E564D4EC9 Q34381899-2627C6D2-DD47-42C9-B021-7A2B02DEDE2E Q34540287-6D653765-1990-4601-8B8D-781D08CB4296 Q37031762-1765C92F-607F-49CD-8C04-8CE9B9F6CED1 Q37755150-13C68D0D-123E-4E1E-B4B7-66EB3529FADD Q38231217-D4A9E780-573D-49A3-92A5-5DDE0CC4F15D Q38902833-6F9B24A7-46EA-4490-8322-65CEBCABACAA Q40081058-7356CA7C-84F5-4494-BC59-CF0DF395B193 Q42980944-3323601C-CFBD-4DF4-8541-FBF41099C143 Q43265538-0B8CA0B9-5617-46E7-BE37-C911D9B23ABB Q43762369-AD3DDC87-975E-4F41-8204-229297C6008D Q45355916-D486266A-7DF8-45FC-A02C-BDF6A735CB22 Q51269774-B0CF1101-50BB-4A5F-B6C7-A2778CFE7E60 Q52345488-64BD5309-F731-4AD6-82A1-B33C2AE7F335 Q53083316-C306FADC-B9AC-4B8A-B2ED-92E6E1566128 Q53287077-A385D8A5-9050-4728-894B-18A85C193CEA

P2860

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q47901999

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh-hant

name

Elevated serum levels of solub ...... with hepatocellular carcinoma.

@en

Elevated serum levels of soluble Fas/APO-1

@nl

type

label

Elevated serum levels of solub ...... with hepatocellular carcinoma.

@en

Elevated serum levels of soluble Fas/APO-1

@nl

prefLabel

Elevated serum levels of solub ...... with hepatocellular carcinoma.

@en

Elevated serum levels of soluble Fas/APO-1

@nl

P1433

Q47901999-3014C6BB-F73D-471A-BAB4-E3A5FE012150

P1476

Q47901999-9232F37D-099A-412E-8EA0-298FAAB38CCE

P2093

Q47901999-2CB3B0BB-E049-40D4-99F6-43FBED9507B6

Q47901999-3C319CB7-C231-46E4-9FE1-3511D04273D5

Q47901999-5920D37F-D260-4F9E-A25C-A58FDC670BD0

Q47901999-6FAE900A-D818-4AF6-9D1D-7C69AD361C42

Q47901999-7EB04FB6-EBA6-4401-93E2-7BAE10DF15B7

Q47901999-8E5AB665-A612-466E-AD92-4F9AEB6191F5

Q47901999-F1518348-ECD3-40C1-BD46-B8A3AF0F8017

Q47901999-F360E9B3-891C-4303-94B4-2362FA2A870B

P2860

Q47901999-22A9A4FF-E121-49E3-B608-E09897958EB1

Q47901999-2E81D540-CEF6-4996-BC79-F6B653B04BDB

Q47901999-3073EA25-9B51-49F2-9652-90415A3F0D3A

Q47901999-4126D7E3-ADE0-49E5-A019-C49BDF36EF40

Q47901999-45164F2D-5F1C-4C09-BBE4-F5217E68B10F

Q47901999-4CA2A538-2EFC-45BC-A33E-14A2997A03A5

Q47901999-561AE45C-0F99-4693-B883-FE79C1D0D3EA

Q47901999-576BD3B7-88AA-4F91-B293-E7AB2A128E67

Q47901999-58B0DCA1-5651-45D1-8658-AED2DB02121F

Q47901999-5B31BE3C-C7EB-41A4-B81A-F3F0D77D75AA

P304

Q47901999-800B0B36-2D7D-4208-9DF9-A7D6B8B4D530

P31

Q47901999-1C4605AF-FCC4-473F-A5CF-13387E949490

P356

Q47901999-9307048A-CDCF-4C34-9DC1-46288E76A19B

P433

Q47901999-31E9102C-3D2A-41F3-9DC2-1BCA229E61EF

P478

Q47901999-07A6AC7C-3861-4AAA-8B99-2403F13EF77D

P50

Q47901999-D1398AAA-5AD4-446F-A36E-D8E30D970E9D

P577

Q47901999-49BE2CF5-228A-443F-9EEE-9EA19C51DB37

P5875

Q47901999-21278E0B-3ED9-4D8D-A5EF-855F5703D369

P698

Q47901999-B1FAD243-5DC9-4997-A74B-C7366A057FFD

P932

Q47901999-2C92CC7E-7F07-4030-A10F-8CC7D518E252

P356

J.1365-2249.1998.00569.X

P1433

Clinical and Experimental Immunology

P1476

Elevated serum levels of solub ...... with hepatocellular carcinoma.

@en

P2093

Jodo S

http://www.w3.org/2001/XMLSchema#string

Kayagaki N

http://www.w3.org/2001/XMLSchema#string

Kobayashi S

http://www.w3.org/2001/XMLSchema#string

Matsunaga T

http://www.w3.org/2001/XMLSchema#string

Nakajima Y

http://www.w3.org/2001/XMLSchema#string

Nakayama N

http://www.w3.org/2001/XMLSchema#string

Ogura N

http://www.w3.org/2001/XMLSchema#string

Okumura K

http://www.w3.org/2001/XMLSchema#string

P2860

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing

Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen

Apoptosis in the pathogenesis and treatment of disease

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.

Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity

Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice.

P304

166-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2249.1998.00569.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

1998-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13635952

http://www.w3.org/2001/XMLSchema#string

P698

9649177

http://www.w3.org/2001/XMLSchema#string

P932

1904963

http://www.w3.org/2001/XMLSchema#string